Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions

2024-512857-25-00 Protocol BLCL-TOF-FDA-04 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 21 May 2024 · End 17 Jun 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol BLCL-TOF-FDA-04

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 38
Countries 1
Sites 1

No medical condition.

Key facts

Sponsor
Bluepharma Industria Farmaceutica S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
21 May 2024 → 17 Jun 2024
Decision date (initial)
2024-05-14
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

No medical condition.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Bluepharma Industria Farmaceutica S.A.

Sponsor organisation
Bluepharma Industria Farmaceutica S.A.
Address
Sao Martinho Do Bispo
City
Coimbra
Postcode
3045-016
Country
Portugal

Scientific contact point

Organisation
Bluepharma Industria Farmaceutica S.A.
Contact name
Medical Affairs Department

Public contact point

Organisation
Bluepharma Industria Farmaceutica S.A.
Contact name
Medical Affairs Department

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Portugal Ended 38 1
Rest of world 0

Investigational sites

Portugal

1 site · Ended
Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
Medical Management, Hospital Da Prelada 0 Floor And 3 rd Floor, Rua Sarmento De Beires 153, Porto

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Portugal 2024-05-21 2024-06-17 2024-05-21 2024-05-28

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-11 Portugal Acceptable
2024-05-08
2024-05-14
2 SUBSTANTIAL MODIFICATION SM-1 2024-06-17 Portugal Acceptable
2024-07-15
2024-07-15